Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
出版年份 2015 全文链接
标题
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
作者
关键词
Cetuximab, Colorectal cancer (CRC), FOLFIRI, IMO-2055 (EMD 1201081), Toll-like receptor 9 agonist (TLR9)
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 4, Pages 701-709
出版商
Springer Nature
发表日期
2015-01-27
DOI
10.1007/s00280-015-2682-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
- (2013) Jean-Pascal Machiels et al. INVESTIGATIONAL NEW DRUGS
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
- (2011) C. Manegold et al. ANNALS OF ONCOLOGY
- Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
- (2011) R. Rosa et al. CLINICAL CANCER RESEARCH
- Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state
- (2011) R. Broering et al. INTERNATIONAL IMMUNOLOGY
- Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Vera Hirsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
- (2011) Clive S. Zent et al. LEUKEMIA & LYMPHOMA
- Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses
- (2010) Xiaopei Huang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Intracellular Toll-like Receptors
- (2010) Amanda L. Blasius et al. IMMUNITY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
- (2010) Youn H. Kim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
- (2009) John A. Thompson et al. Clinical Genitourinary Cancer
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
- (2008) Maja A. Hofmann et al. JOURNAL OF IMMUNOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now